-
Product Insights
NewCytomegalovirus (HHV-5) Infections – Drugs In Development, 2024
Empower your strategies with our Cytomegalovirus (HHV-5) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Cytomegalovirus (CMV) is virus in the herpes family, also called HHV-5. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, and hearing, neurological, and developmental problems. The predisposing factors are direct contact with an infected surface or individual, weakened immune system, and congenital factors. It may be diagnosed by blood or urine tests. The condition may be...
-
Product Insights
NewMumps – Drugs In Development, 2024
Empower your strategies with our Mumps – Drugs In Development, 2024 report and make more profitable business decisions. Mumps is a contagious disease that leads to painful swelling of the salivary glands. The mumps are caused by a virus that is spread from person to person by respiratory droplets (for example, when you sneeze) or by direct contact with items that have been contaminated with infected saliva. Symptoms include fever, face pain, headache, sore throat, swelling of the temples or jaw...
-
Product Insights
NewRubulavirus Infections – Drugs In Development, 2024
Empower your strategies with our Rubulavirus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Mumps is a viral illness caused by a paramyxovirus, a member of the Rubulavirus family. The average incubation period for mumps is 16 to 18 days, with a range of 12 to 25 days. It is highly infectious and spreads rapidly among people living in close quarters. It is transmitted by respiratory droplets, direct contact, or contaminated objects. The Rubulavirus Infections drugs...
-
Product Insights
NewDermatomyositis – Drugs In Development, 2024
Empower your strategies with our Dermatomyositis – Drugs In Development, 2024 report and make more profitable business decisions. Dermatomyositis is a rare inflammatory disease characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids. The Dermatomyositis drugs in development market research report provide comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage...
-
Product Insights
NewMethicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Drugs In Development, 2024
Empower your strategies with our Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Methicillin-susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually causes skin infections, but can also cause pneumonia and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea, and abdominal pain. Predisposing factors include weakened immune systems, burns, and surgical wounds. The Methicillin-Susceptible Staphylococcus aureus (MSSA)...
-
Product Insights
NewGeneralized Anxiety Disorder (GAD) – Drugs In Development, 2024
Empower your strategies with our Generalized Anxiety Disorder (GAD) – Drugs In Development, 2024 report and make more profitable business decisions. Generalized anxiety disorder is a mental health disorder that produces fear, worry, and a constant feeling of being overwhelmed. It is characterized by excessive, persistent, and unrealistic worry about everyday things. Individuals with GAD typically experience heightened anxiety and apprehension, anticipating negative outcomes in everyday situations. Physical symptoms may include restlessness, muscle tension, fatigue, and difficulty concentrating. Unlike specific phobias...
-
Product Insights
NewSicca Syndrome (Sjogren) – Drugs In Development, 2024
Empower your strategies with our Sicca Syndrome (Sjogren) – Drugs In Development, 2024 report and make more profitable business decisions. Sjogren's syndrome is an autoimmune disease. It involves the inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling, and stiffness. Predisposing factors include age, sex, and rheumatic disease. The Sicca Syndrome (Sjogren) drugs in development market research report provide comprehensive...